Shuangze Han
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shuangze Han has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Jinzhuang Liao
Department of Radiology, The Third Xiangya Hospital of Central South University, Changsha, China
1 shared publication - Ming Li
School of Stomatology, Hunan University of Chinese Medicine, Changsha, People’s Republic of China
1 shared publication - Shuliang Yang
College of Energy State Key Laboratory of Physical Chemistry of Solid Surfaces Xiamen University Xiamen Fujian China
1 shared publication - Wei Li
Department of Radiology, the Third Xiangya Hospital of Central South University, Changsha, People’s Republic of China
1 shared publication Xiaoying Li
Department of Radiology
1 shared publication- Xinfang Yu
Key Laboratory of Carcinogenesis and Cancer Invasion of Chinese Ministry of Education, XiangYa Hospital, Central South University, Changsha, China
1 shared publication
Latest Publications
- 1 January 2023
- Published by World Scientific Pub Co Pte Ltd in The American Journal of Chinese Medicine
- Vol. 51 (08) , 2221-2241
Isoliquiritigenin Inhibits Oral Squamous Cell Carcinoma and Overcomes Chemoresistance by Destruction of Survivin
The oncoprotein survivin plays a pivotal role in controlling cell division and preventing apoptosis by inhibiting caspase activation. Its significant contribution to tumorigenesis and therapeutic resistance has been well established. Isoliquiritigenin (ISL), a natural compound, has been recognized for its powerful inhibitory effects against various tumors. However, whether ISL exerts regulatory effects on survivin and its underlying mechanism in oral squamous cell carcinoma (OSCC) remains unclear. Here, we found that ISL inhibited the viability and colony formation of OSCC, and promoted their apoptosis. The immunoblotting data showed that ISL treatment significantly decreased survivin expression. Mechanistically, ISL suppressed survivin phosphorylation on Thr34 by deregulating Akt-Wee1-CDK1 signaling, which facilitated survivin for ubiquitination degradation. ISL inhibited CAL27 tumor growth and decreased p-Akt and survivin expression in vivo. Meanwhile, survivin overexpression caused cisplatin resistance of OSCC cells. ISL alone or combined with cisplatin overcame chemoresistance in OSCC cells. Overall, our results revealed that ISL exerted potent inhibitory effects via inducing Akt-dependent survivin ubiquitination in OSCC cells.
- 1 January 2023
- Published by World Scientific Pub Co Pte Ltd in The American Journal of Chinese Medicine
- Vol. 51 (08) , 2221-2241
Isoliquiritigenin Inhibits Oral Squamous Cell Carcinoma and Overcomes Chemoresistance by Destruction of Survivin
The oncoprotein survivin plays a pivotal role in controlling cell division and preventing apoptosis by inhibiting caspase activation. Its significant contribution to tumorigenesis and therapeutic resistance has been well established. Isoliquiritigenin (ISL), a natural compound, has been recognized for its powerful inhibitory effects against various tumors. However, whether ISL exerts regulatory effects on survivin and its underlying mechanism in oral squamous cell carcinoma (OSCC) remains unclear. Here, we found that ISL inhibited the viability and colony formation of OSCC, and promoted their apoptosis. The immunoblotting data showed that ISL treatment significantly decreased survivin expression. Mechanistically, ISL suppressed survivin phosphorylation on Thr34 by deregulating Akt-Wee1-CDK1 signaling, which facilitated survivin for ubiquitination degradation. ISL inhibited CAL27 tumor growth and decreased p-Akt and survivin expression in vivo. Meanwhile, survivin overexpression caused cisplatin resistance of OSCC cells. ISL alone or combined with cisplatin overcame chemoresistance in OSCC cells. Overall, our results revealed that ISL exerted potent inhibitory effects via inducing Akt-dependent survivin ubiquitination in OSCC cells.
- Open Access
- 1 January 2022
- Published by Wiley in BioMed Research International
- Vol. 2022 (1) , 5687832
Licochalcone A Promotes the Ubiquitination of c‐Met to Abrogate Gefitinib Resistance
Met proto‐oncogene (MET) amplification and tyrosine‐protein kinase Met (c‐Met) overexpression confer gefitinib resistance in non‐small cell lung cancer (NSCLC). The natural product Licochalcone A (Lico A) exhibits a broad range of inhibitory effects against various tumors. However, the effects of Lico A on c‐Met signaling and gefitinib resistance in NSCLC remain unclear. In the present study, Lico A efficiently overcame gefitinib‐acquired resistance in NSCLC cells by suppressing c‐Met signaling. Lico A decreased cell viability and colony formation dose‐dependently and impaired in vivo tumorigenesis of gefitinib‐resistant HCC827 and PC‐9 cells. Furthermore, Lico A induced intrinsic apoptosis and upregulated the protein expression levels of cleaved poly (ADP‐ribose) polymerase and cleaved caspase 3. Lico A promoted the interaction between c‐Met and E3 ligase c‐Casitas B‐lineage lymphoma (Cbl), which enhanced c‐Cbl‐mediated c‐Met ubiquitination and degradation. Depletion of c‐Cbl compromised Lico A‐induced c‐Met ubiquitination and its inhibitory efficacy in gefitinib‐resistant NSCLC cells. Taken together, the results suggest that Lico A is a promising antitumor agent that might be used to overcome c‐Met overexpression‐mediated gefitinib resistance in NSCLC cells.
- 1 January 2022
- Published by Wiley in BioMed Research International
- Vol. 2022 (1) , 5687832
Open AccessLicochalcone A Promotes the Ubiquitination of c‐Met to Abrogate Gefitinib Resistance
Met proto‐oncogene (MET) amplification and tyrosine‐protein kinase Met (c‐Met) overexpression confer gefitinib resistance in non‐small cell lung cancer (NSCLC). The natural product Licochalcone A (Lico A) exhibits a broad range of inhibitory effects against various tumors. However, the effects of Lico A on c‐Met signaling and gefitinib resistance in NSCLC remain unclear. In the present study, Lico A efficiently overcame gefitinib‐acquired resistance in NSCLC cells by suppressing c‐Met signaling. Lico A decreased cell viability and colony formation dose‐dependently and impaired in vivo tumorigenesis of gefitinib‐resistant HCC827 and PC‐9 cells. Furthermore, Lico A induced intrinsic apoptosis and upregulated the protein expression levels of cleaved poly (ADP‐ribose) polymerase and cleaved caspase 3. Lico A promoted the interaction between c‐Met and E3 ligase c‐Casitas B‐lineage lymphoma (Cbl), which enhanced c‐Cbl‐mediated c‐Met ubiquitination and degradation. Depletion of c‐Cbl compromised Lico A‐induced c‐Met ubiquitination and its inhibitory efficacy in gefitinib‐resistant NSCLC cells. Taken together, the results suggest that Lico A is a promising antitumor agent that might be used to overcome c‐Met overexpression‐mediated gefitinib resistance in NSCLC cells.